Rick Acquires Allergan for $63 Billion

Quote
anonymous said:
Headline:

“Bloated 1 product company buys bloated 1 product company.”

Can’t believe Red Font Zodiac Stock Killa didn’t
know about this #BASTA
Click to expand...

Indeed, the info I had was Rick was looking at TG Therapeutics.
Mike Ball who was former CEO of Allergan and then took over Hospira (Abbott’s spun off HPD) which was sold to PFE. Ball made $80M TAX Free. He WAS involved in this deal along with Miles White.
You saw what Pfizer did selling off injectables and Device end to ICU and it will be a bloodbath for Allergan AND Abbvie employee’s. Rick LOST $19 Billion in market cap today for a third rate company with ZERO pipeline. This is the biggest blunder of Rick career. I told you peeps this lying bum should have been fired LONG AGO
 


















This isn’t a done deal YET. AbbVie AND Allergan shareholders must approve the transaction. Obviously Allergan shareholders will vote yes. THEN there are big regulatory hurdles to overcome. Projected close date in Q120. What in God’s name was Rick thinking? First of all Evolus (ELOS) has a cheaper injection that’s already FDA approved that will impact Botox. ALSO, Restasis, has generic competition beginning in 2024 and is already experiencing price erosion. The FTC and DOJ will oversee this acquisition and inversion laws are in question. Financial engineering by Abbvie that is a disaster. The Street lost ALL confidence in Rick and Abbvie. The debt load now rivals some junk company’s debt.
SHAME ON YOU RICK
 






Guys weeds legal! Just relax.

88 billion in debt is nothing for a company with 2nd highest free cash flow in the biz. (Post acquisition)Dividend is safe and will increase.
Today’s loss is due to merger arbitrage and not on fundamentals.
We were stuck in range waiting to see what the Humira LOE would do, now we don’t care because 5000 people turn 65 every day until 2025 when it starts to decline. That demographic has the largest chunk of wealth our country has ever seen. Aesthetics biz is 4billion, which will climb everyday till 2025.
The avg age of a CLL patient is 60, more CLL patients everyday.
Synthroid is gonna do a billion next year and it’s 89% profit so there’s 890 million in free cash every year for 1 drug.
Creon expansion to 1.5 billion.
I could go on and on but haters gonna hate.
6.4% dividend yield and everyday the stock goes down the yield go s up.
 






anonymous said:
This isn’t a done deal YET. AbbVie AND Allergan shareholders must approve the transaction. Obviously Allergan shareholders will vote yes. THEN there are big regulatory hurdles to overcome. Projected close date in Q120. What in God’s name was Rick thinking? First of all Evolus (ELOS) has a cheaper injection that’s already FDA approved that will impact Botox. ALSO, Restasis, has generic competition beginning in 2024 and is already experiencing price erosion. The FTC and DOJ will oversee this acquisition and inversion laws are in question. Financial engineering by Abbvie that is a disaster. The Street lost ALL confidence in Rick and Abbvie. The debt load now rivals some junk company’s debt.
SHAME ON YOU RICK
Click to expand...


Allergan's best hope is going to be another bust like Rova T.
Abicipar for AMD has been shown to have safety issues that will prevent it from competing effectively against other proposed treatments for wet AMD.
 


















Everyone needs to pump the brakes on the name calling because at the merge we will be one in whatever form it takes. Let’s do our jobs until that happens and let the best survive. We have a long half a year to wait let’s not make it worse by demeaning each company both have good points and bad and hopefully the new entity will be a great opportunity for everyone.
 






I started with Forest Pharmaceuticals in 2005 and left AGN for Abbvie in 2017. When Howard Solomon (uncle Howie we called him) was CEO of Forest, I had vast opportunities to move up and laterally throughout the country to many sale roles. However, when Brent came on as CEO and evolved Forest into Actavis, now AGN the opportunities dried up and layoffs were rampant.

From June 2013 to September 2017, I had to assure, reassure, and keep the fear mongering noise down in order for my reps to do there jobs. Atlas, here I am, confronted with this acquisition and my cellphone has been ringing since 9 am of my Abbvie reps and colleagues asking what to expect? I don't really know, now that Saunders has a seat on the board of directors but what I know is that his power hungry crony RDs like Kilcoyne, DeFoe, Wheeler, Montgomery, Cox, Giarratano, Belak, Kenny, and Heuer better tread lightly and understand this is Abbvie, no longer AGN.

The grass was much greener over here when I made the jump and it had better stay green. This is actually a great place to work with realistic goals and a great group of folks who enjoys coming to work, do their work and be left alone and not threaten by filtered down threats via DMs on a daily basis.
Goodluck to all...
 












Allergans operating LOSS for Q1 ballooned to $2.4 billion, with the write down of their depression drug that tanked in clinical trials. AbbVie is borrowing $38 billion to fund the cash portion of the buyout price, and shouldering $24 billion in Allergan debt? CFO Bob Michael told analysts on the call the company will work to reduce debt by $15 to $18 billion within three years, while extracting $2 billion in cost savings from combined operations with nearly 47,000 employees and facilities scattered across four continents. Where will the $2B cost savings extraction come from? Answer Massive Lay offs and sell offs of divisions How will you reduce the $18B in 36 months? Wow they are blowing smoke out their ass and STREET and investors not buying it.
 






anonymous said:
Everyone needs to pump the brakes on the name calling because at the merge we will be one in whatever form it takes. Let’s do our jobs until that happens and let the best survive. We have a long half a year to wait let’s not make it worse by demeaning each company both have good points and bad and hopefully the new entity will be a great opportunity for everyone.
Click to expand...

Well stated but easier said than done. Carry on soldier!!
To the non sheep who get it, Go sell pain cream on abbvies time and dime and double dip.
 






Do you realize how many shares of AGN Rick and C Suite will get?
Holy Mackerel, and Rick gives a whopping 19.2% of non floated Abbv shares to AGN shareholders?
Wait until EOLS starts reporting good numbers for comparative injections putting bear pressure on AGNs only cash cow.
 






anonymous said:
I started with Forest Pharmaceuticals in 2005 and left AGN for Abbvie in 2017. When Howard Solomon (uncle Howie we called him) was CEO of Forest, I had vast opportunities to move up and laterally throughout the country to many sale roles. However, when Brent came on as CEO and evolved Forest into Actavis, now AGN the opportunities dried up and layoffs were rampant.

From June 2013 to September 2017, I had to assure, reassure, and keep the fear mongering noise down in order for my reps to do there jobs. Atlas, here I am, confronted with this acquisition and my cellphone has been ringing since 9 am of my Abbvie reps and colleagues asking what to expect? I don't really know, now that Saunders has a seat on the board of directors but what I know is that his power hungry crony RDs like Kilcoyne, DeFoe, Wheeler, Montgomery, Cox, Giarratano, Belak, Kenny, and Heuer better tread lightly and understand this is Abbvie, no longer AGN.

The grass was much greener over here when I made the jump and it had better stay green. This is actually a great place to work with realistic goals and a great group of folks who enjoys coming to work, do their work and be left alone and not threaten by filtered down threats via DMs on a daily basis.
Goodluck to all...
Click to expand...


Well stated, you definitely know the dirty ones. Did you know Henry Gosebruch is Chief Strategy Officer at Abbvie? He brokered the Forest Sale to Actavis and also brokered Merck’s takeover of Cubist? He FAILED on Shire deal and that’s how he got hired here. Yes Saunders will be on BOD
 






anonymous said:
I started with Forest Pharmaceuticals in 2005 and left AGN for Abbvie in 2017. When Howard Solomon (uncle Howie we called him) was CEO of Forest, I had vast opportunities to move up and laterally throughout the country to many sale roles. However, when Brent came on as CEO and evolved Forest into Actavis, now AGN the opportunities dried up and layoffs were rampant.

From June 2013 to September 2017, I had to assure, reassure, and keep the fear mongering noise down in order for my reps to do there jobs. Atlas, here I am, confronted with this acquisition and my cellphone has been ringing since 9 am of my Abbvie reps and colleagues asking what to expect? I don't really know, now that Saunders has a seat on the board of directors but what I know is that his power hungry crony RDs like Kilcoyne, DeFoe, Wheeler, Montgomery, Cox, Giarratano, Belak, Kenny, and Heuer better tread lightly and understand this is Abbvie, no longer AGN.

The grass was much greener over here when I made the jump and it had better stay green. This is actually a great place to work with realistic goals and a great group of folks who enjoys coming to work, do their work and be left alone and not threaten by filtered down threats via DMs on a daily basis.
Goodluck to all...
Click to expand...

You forgot Renner and Brandt. Those two take the cake from the others you have mentioned combined. Fortunately for the Abvie folks Deegan is not around
 












anonymous said:
Legacy Forest Pharmaceutical reps, legacy Actavis reps and Allergan reps are worst than Abbott robot reps. Allergan's culture is an egregious antonym to ours on a multitude scale of commerical operations. You'll see soon.
Click to expand...


Lol. You’re mad? Their sales force is Currently driving a product in a generic flooded market to 1 billion in 3 years and another product has close to 50% market share. But they’re “robots” I’m guessing a AGN rep stole your lunch in an office.... just because they know their products and competitors and drive business through that rather than flirting and tossing their hair doesn’t mean they’re robots.
 






anonymous said:
I started with Forest Pharmaceuticals in 2005 and left AGN for Abbvie in 2017. When Howard Solomon (uncle Howie we called him) was CEO of Forest, I had vast opportunities to move up and laterally throughout the country to many sale roles. However, when Brent came on as CEO and evolved Forest into Actavis, now AGN the opportunities dried up and layoffs were rampant.

From June 2013 to September 2017, I had to assure, reassure, and keep the fear mongering noise down in order for my reps to do there jobs. Atlas, here I am, confronted with this acquisition and my cellphone has been ringing since 9 am of my Abbvie reps and colleagues asking what to expect? I don't really know, now that Saunders has a seat on the board of directors but what I know is that his power hungry crony RDs like Kilcoyne, DeFoe, Wheeler, Montgomery, Cox, Giarratano, Belak, Kenny, and Heuer better tread lightly and understand
this is Abbvie, no longer AGN.

The grass was much greener over here when I made the jump and it had better stay green. This is actually a great place to work with realistic goals and a great group of folks who enjoys coming to work, do their work and be left alone and not threaten by filtered down threats via DMs on a daily basis.
Goodluck to all...
Click to expand...


This is pretty accurate. I too was at Forest/Actavis/Allergan for about 18 years. Forest was very well run with a great atmosphere and culture. Everybody loved our CEO Howard Solomon and we’d breaj our backs for him. Then here comes Saunders. Every meeting became threatening. It was a Fear Factor sales job. Some regions put reps at “Below Expectations” unless the reps were in the top 25%.

God help y’all if Carry Renner has a role with your company. Saunders will ruin your company. He’s been a disaster in most every place he’s been. He ruined Forest/ Allergan. You’re about to be in a dark, heavy handed, threatening environment with some of the thickest micromanagement that you’ve ever seen.
 






I came here because Abbvie is a great company with a promising pipeline, and hopefully has some semblance of job security. I am truly questioning the future after today's news. I hope the higher ups see something I don't .
 






Top Bottom
Back
Quote